Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes.

Xiuli Liu Xiuli Liu,Jifeng Zhang Jifeng Zhang,Wenzong Zhou Wenzong Zhou,Jingwang Liu Jingwang Liu,Yingli Wang Yingli Wang

doi:10.14715/cmb/2023.69.2.18

Xiuli Liu Xiuli Liu, Jifeng Zhang Jifeng Zhang + Show 3 more

Open Access

https://doi.org/10.14715/cmb/2023.69.2.18

Copy DOI

Abstract

This study was to observe the effects of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. For this purpose, a total of 126 chronic heart failure patients complicated with diabetes admitted to our hospital from September 2020 to October 2021 were selected and divided into a control group and an observation group by random number table method, with 63 cases in each group. The control group received conventional drug treatment, and the observation group received fenofibrate treatment on the basis of the control group. After 12 months follow-up, the levels of blood lipid, sICAM-1, ET-1 were compared between the two groups at 3 months before and after treatment and 6, 12 months after treatment. Results showed that after 3 months of treatment, LDL-C, TG and TC were lower in the observation group than in the control group, showing a statistically significant difference (P<0.05). After 3 months of treatment, HDL-C was higher in the observation group than in the control group, showing a difference (P<0.05). After 3 months of treatment, sICAM-1 and ET-1 were lower in the observation group than in the control group, showing a difference (P<0.05). There was no significant difference in mortality after 6 months of treatment, re-hospitalization rate and mortality after 12 months of treatment between the two groups (P>0.05). The re-hospitalization rate of the observation group was 4.76% (3/63) after 6 months of treatment, which was lower than that of the control group in the same period, showing a significant difference (P<0.05). The conclusion was that fenofibrate can regulate blood lipids in chronic heart failure patients complicated with diabetes, inhibit sICAM-1 and ET-1, and reduce the re-hospitalization rate within 6 months after treatment. However, the effects on long-term re-hospitalization rate and mortality risk are consistent with those of conventional treatment.

Full Text